Xenon Pharmaceuticals Inc.
XENE
Rang in Aktien
#4532
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company... Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
Aktienkurs
$34.95
Zuletzt synchronisiert: 2026-10-19
Marktkapitalisierung
$3.38B
Veränderung (1 Tag)
4.36%
Veränderung (1 Jahr)
-19.54%
Land
CA
Handel Xenon Pharmaceuticals Inc. (XENE)
Kategorie
Healthcare
Anzahl der ausstehenden Aktien von Xenon Pharmaceuticals Inc. (XENE)
Anzahl der ausstehenden Aktien zum June 2026: 99.61M
Laut den neuesten Finanzberichten und dem Aktienkurs von Xenon Pharmaceuticals Inc. beträgt die aktuelle Anzahl der ausstehenden Aktien 99.61M. Am Ende von December 2023 hatte das Unternehmen 66.89M ausstehende Aktien. Die Anzahl der ausstehenden Aktien wird normalerweise durch Aktiensplits und Aktienrückkäufe beeinflusst.
Verlauf der ausstehenden Aktien von Xenon Pharmaceuticals Inc. (XENE) von 2011 bis 2026
Ausstehende Aktien am Ende jedes Jahres
| Jahr | Ausstehende Aktien | ändert |
|---|---|---|
| 2026 (TTM) | 99.61M | 27.88% |
| 2024 | 77.89M | 16.45% |
| 2023 | 66.89M | 10.48% |
| 2022 | 60.54M | 38.77% |
| 2021 | 43.63M | 26.30% |
| 2020 | 34.54M | 33.17% |
| 2019 | 25.94M | 33.53% |
| 2018 | 19.43M | 8.01% |
| 2017 | 17.99M | 16.08% |
| 2016 | 15.49M | 8.48% |
| 2015 | 14.28M | 2.89% |
| 2014 | 13.88M | 52.78% |
| 2013 | 9.09M | 582.58% |
| 2012 | 1.33M | 0.14% |
| 2011 | 1.33M | 0.00% |
Ausstehende Aktien bei ähnlichen Unternehmen oder Wettbewerbern
| Unternehmen | Ausstehende Aktien | Unterschied | Land |
|---|---|---|---|
| 253.90M | 154.89% |
US
|
|
| 396.00M | 297.55% |
US
|
|
| 478.91M | 380.79% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -37.57% |
NL
|
